Aralez Pharmaceuticals (NASDAQ:ARLZ) – Research analysts at Zacks Investment Research raised their FY2018 earnings per share estimates for shares of Aralez Pharmaceuticals in a research report issued on Monday. Zacks Investment Research analyst D. Bautz now expects that the company will earn ($0.70) per share for the year, up from their previous estimate of ($0.77). Zacks Investment Research also issued estimates for Aralez Pharmaceuticals’ FY2019 earnings at ($0.66) EPS and FY2020 earnings at ($0.60) EPS.

How to Become a New Pot Stock Millionaire

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Tuesday, March 13th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Aralez Pharmaceuticals had a negative net margin of 118.18% and a negative return on equity of 170.42%. The firm had revenue of $28.02 million for the quarter, compared to analysts’ expectations of $25.75 million.

Other equities analysts also recently issued research reports about the stock. Bloom Burton downgraded shares of Aralez Pharmaceuticals from a “buy” rating to an “accumulate” rating in a report on Wednesday, March 14th. HC Wainwright set a $6.00 target price on shares of Aralez Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. Finally, Chardan Capital reissued a “buy” rating on shares of Aralez Pharmaceuticals in a report on Tuesday.

ARLZ stock traded up $0.03 during mid-day trading on Wednesday, hitting $1.64. 206,227 shares of the stock traded hands, compared to its average volume of 640,239. Aralez Pharmaceuticals has a 1 year low of $0.95 and a 1 year high of $2.98. The company has a debt-to-equity ratio of 18.05, a current ratio of 0.78 and a quick ratio of 0.68. The stock has a market capitalization of $113.25, a P/E ratio of -0.87 and a beta of 1.41.

An institutional investor recently raised its position in Aralez Pharmaceuticals stock. Goldman Sachs Group Inc. lifted its stake in Aralez Pharmaceuticals (NASDAQ:ARLZ) by 159.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 261,606 shares of the company’s stock after buying an additional 160,621 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.39% of Aralez Pharmaceuticals worth $371,000 at the end of the most recent reporting period. Institutional investors own 17.86% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Comments on Aralez Pharmaceuticals’ FY2018 Earnings (ARLZ)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with's FREE daily email newsletter.